<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab1">
 <label>Table 1</label>
 <caption>
  <p>Demographics and baseline characteristics</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Characteristic</th>
    <th>Phase 1 (
     <italic>n</italic> = 4)
    </th>
    <th>Phase 2 (
     <italic>n</italic> = 44)
    </th>
    <th>Total (
     <italic>n</italic> = 48)
    </th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>Age, years, median (range)</td>
    <td>72.5 (42–76)</td>
    <td>69.0 (32–79)</td>
    <td>69.5 (32–79)</td>
   </tr>
   <tr>
    <td colspan="4">Sex, 
     <italic>n</italic> (%)
    </td>
   </tr>
   <tr>
    <td> Male</td>
    <td>1 (25)</td>
    <td>30 (68)</td>
    <td>31 (65)</td>
   </tr>
   <tr>
    <td> Female</td>
    <td>3 (75)</td>
    <td>14 (32)</td>
    <td>17 (35)</td>
   </tr>
   <tr>
    <td colspan="4">ECOG PS, 
     <italic>n</italic> (%)
    </td>
   </tr>
   <tr>
    <td> 0</td>
    <td>2 (50)</td>
    <td>27 (61)</td>
    <td>29 (60)</td>
   </tr>
   <tr>
    <td> 1</td>
    <td>2 (50)</td>
    <td>17 (39)</td>
    <td>19 (40)</td>
   </tr>
   <tr>
    <td colspan="4">Disease classification, 
     <italic>n</italic> (%)
    </td>
   </tr>
   <tr>
    <td> Peripheral T cell lymphoma, NOS</td>
    <td>1 (25)</td>
    <td>21 (48)</td>
    <td>22 (46)</td>
   </tr>
   <tr>
    <td> Angioimmunoblastic T cell lymphoma</td>
    <td>2 (50)</td>
    <td>17 (39)</td>
    <td>19 (40)</td>
   </tr>
   <tr>
    <td colspan="4"> Anaplastic large cell lymphoma</td>
   </tr>
   <tr>
    <td>  ALK-positive</td>
    <td>1 (25)</td>
    <td>0 (0)</td>
    <td>1 (2)</td>
   </tr>
   <tr>
    <td>  ALK-negative</td>
    <td>0 (0)</td>
    <td>2 (5)</td>
    <td>2 (4)</td>
   </tr>
   <tr>
    <td> Extranodal T cell/NK cell lymphoma, nasal type</td>
    <td>0 (0)</td>
    <td>1 (2)</td>
    <td>1 (2)</td>
   </tr>
   <tr>
    <td> Transformed mycosis fungoides</td>
    <td>0 (0)</td>
    <td>1 (2)</td>
    <td>1 (2)</td>
   </tr>
   <tr>
    <td> Other
     <sup>a</sup>
    </td>
    <td>0 (0)</td>
    <td>2 (5)</td>
    <td>2 (4)</td>
   </tr>
   <tr>
    <td colspan="4">Ann Arbor classification,
     <sup>b</sup>
     <italic>n</italic> (%)
    </td>
   </tr>
   <tr>
    <td> Stage I</td>
    <td>0 (0)</td>
    <td>1 (2)</td>
    <td>1 (2)</td>
   </tr>
   <tr>
    <td> Stage II</td>
    <td>3 (75)</td>
    <td>9 (20)</td>
    <td>12 (25)</td>
   </tr>
   <tr>
    <td> Stage III</td>
    <td>0 (0)</td>
    <td>20 (45)</td>
    <td>20 (42)</td>
   </tr>
   <tr>
    <td> Stage IV</td>
    <td>1 (25)</td>
    <td>13 (30)</td>
    <td>14 (29)</td>
   </tr>
   <tr>
    <td colspan="4">LDH (baseline)</td>
   </tr>
   <tr>
    <td> Low/normal</td>
    <td>2(50.0)</td>
    <td>24 (55)</td>
    <td>26 (54)</td>
   </tr>
   <tr>
    <td> High</td>
    <td>2(50.0)</td>
    <td>20 (45)</td>
    <td>22(46)</td>
   </tr>
   <tr>
    <td colspan="4">Prior treatment regimens</td>
   </tr>
   <tr>
    <td> Median (range)</td>
    <td>2 (1–9)</td>
    <td>2 (1–6)</td>
    <td>2 (1–9)</td>
   </tr>
   <tr>
    <td> Chemotherapy, 
     <italic>n</italic> (%)
    </td>
    <td>4 (100)</td>
    <td>44 (100)</td>
    <td>48 (100)</td>
   </tr>
   <tr>
    <td> ASCT, 
     <italic>n</italic> (%)
    </td>
    <td>0 (0)</td>
    <td>3 (7)</td>
    <td>3 (6)</td>
   </tr>
   <tr>
    <td> Radiation therapy, 
     <italic>n</italic> (%)
    </td>
    <td>1 (25)</td>
    <td>5 (11)</td>
    <td>6 (13)</td>
   </tr>
   <tr>
    <td> Monoclonal antibody, 
     <italic>n</italic> (%)
    </td>
    <td>1 (25)</td>
    <td>3 (7)</td>
    <td>4 (8)</td>
   </tr>
   <tr>
    <td> Corticosteroid, 
     <italic>n</italic> (%)
    </td>
    <td>1 (25)</td>
    <td>2 (5)</td>
    <td>3 (6)</td>
   </tr>
   <tr>
    <td colspan="4">Response to most recent treatment regimen, 
     <italic>n</italic> (%)
    </td>
   </tr>
   <tr>
    <td> CR/CRu</td>
    <td>3 (75)</td>
    <td>20 (45)</td>
    <td>23 (48)</td>
   </tr>
   <tr>
    <td> PR</td>
    <td>1 (25)</td>
    <td>24 (55)</td>
    <td>25 (52)</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>
   <italic>ALK</italic> anaplastic lymphoma kinase, 
   <italic>ASCT</italic> autologous hematopoietic stem cell transplant, 
   <italic>CR</italic> complete response, 
   <italic>CRu</italic> unconfirmed complete response, 
   <italic>ECOG PS</italic> Eastern Cooperative Oncology Group performance status, 
   <italic>LDH</italic> lactate dehydrogenase, 
   <italic>NK cell</italic> natural killer cell, 
   <italic>NOS</italic> not otherwise specified, 
   <italic>PR</italic> partial response, 
   <italic>SD</italic> standard deviation
  </p>
  <p>
   <sup>a</sup>Includes two cases judged to be plasmablastic lymphoma and follicular dendritic cell sarcoma, respectively, on the independent central pathology review
  </p>
  <p>
   <sup>b</sup>Classification for PTCLs other than transformed mycosis fungiodes. The case of transformed mycosis fungiodes was stage IV by the ISCL-EORTC classification
  </p>
 </table-wrap-foot>
</table-wrap>
